Authors: Daniel Castellano Enrique Grande Juan Valle Jaume Capdevila Diane ReidyLagunes Juan Manuel O’Connor Eric Raymond
Publish Date: 2014/12/06
Volume: 75, Issue: 6, Pages: 1099-1114
Abstract
Neuroendocrine tumors NETs are rare tumors that have been increasing in incidence over the last 30 years with no significant changes in survival As survival of patients with these tumors depends greatly on stage and histology early diagnosis classification and staging of tumors in patients in whom NETs are suspected are of great importance Surgery either with curative or palliative intent is the mainstay of treatment for localized NETs Therapeutic options for this disease almost invariably include somatostatin analogs to alleviate the symptoms of excessive hormone secretion Other approaches for advanced disease may include hepatic artery embolization or ablation peptide receptor radionuclide therapy and systemic chemotherapy Recent advances regarding the signaling pathways involved in tumor development have allowed the development of novel targeted therapies However due to the lack of prognostic molecular markers to identify highrisk patients and the absence of a common pathogenesis in all patients treatment selection is often empirical There is therefore a need to establish a consensus for the treatment of this disease and to provide evidencebased clinical recommendations and algorithms to optimize and individualize the treatment and followup for these patients
Keywords: